Reasons for discontinuation of previous TNF inhibitor
| Reason | Rituximab | Alternative TNF inhibitor | All patients |
|---|---|---|---|
| Full analysis population | (n=604) | (n=507) | (n=1111) |
| Inefficacy | 465 (77.0) | 362 (71.4) | 827 (74.4) |
| Primary* | 214 (46.0) | 115 (31.8) | 329 (39.8) |
| Secondary* | 244 (52.5) | 233 (64.4) | 477 (57.7) |
| Missing data | 7 (1.5) | 14 (3.9) | 21 (2.5) |
| Intolerance | 128 (21.2) | 136 (26.6) | 263 (23.7) |
| Other | 11 (1.8) | 10 (2.0) | 21 (1.9) |
| Primary effectiveness population | (n=405) | (n=323) | (n=728) |
| Inefficacy | 311 (76.8) | 236 (73.1) | 547 (75.1) |
| Primary* | 130 (41.8) | 74 (31.4) | 204 (37.3) |
| Secondary* | 176 (56.6) | 156 (66.1) | 332 (60.7) |
| Missing data | 5 (1.6) | 6 (2.5) | 11 (20.1) |
| Intolerance | 89 (22.0) | 79 (24.5) | 168 (23.1) |
| Other | 6 (1.2) | 8 (2.5) | 13 (1.8) |
Values are number (%).
*Primary inefficacy, lack of initial clinical response to TNF inhibitor treatment; secondary inefficacy, development of an inadequate response over time after an initial clinical response.
TNF, tumour necrosis factor.